Cutaneous inflammation alters the function of primary afferents and gene expression in the affected dorsal root ganglia (DRG). However, specific mechanisms of injury-induced peripheral afferent sensitization and behavioral hypersensitivity during development are not fully understood. Recent studies in children suggest a potential role for growth hormone (GH) in pain modulation. Growth hormone modulates homeostasis and tissue repair after injury, but how GH affects nociception in neonates is not known. To determine whether GH played a role in modulating sensory neuron function and hyperresponsiveness during skin inflammation in young mice, we examined behavioral hypersensitivity and the response properties of cutaneous afferents using an ex vivo hairy skin-saphenous nerve-DRG-spinal cord preparation. Results show that inflammation of the hairy hind paw skin initiated at either postnatal day 7 (P7) or P14 reduced GH levels specifically in the affected skin. Furthermore, pretreatment of inflamed mice with exogenous GH reversed mechanical and thermal hypersensitivity in addition to altering nociceptor function. These effects may be mediated through an upregulation of insulin-like growth factor 1 receptor (IGFr1) as GH modulated the transcriptional output of IGFr1 in DRG neurons in vitro and in vivo. Afferent-selective knockdown of IGFr1 during inflammation also prevented the observed injury-induced alterations in cutaneous afferents and behavioral hypersensitivity similar to that after GH pretreatment. These results suggest that GH can block inflammation-induced nociceptor sensitization during postnatal development leading to reduced painlike behaviors, possibly by suppressing the upregulation of IGFr1 within DRG.
Introduction
Peripheral sensitization occurs after injury at all ages, 20, 49, 61, 71 but insults sustained during development have the potential to be much more detrimental to the long-term outcomes of neonates. 59, 67, 68 The neonatal period is a critical stage for the structural and functional reorganization of the sensory system. 11, 14, [36] [37] [38] [39] For example, there is a known switch in neurotrophic factor sensitivity during the first week of life, whereby sensory neurons downregulate trkA and upregulate c-ret rendering them responsive to glial cell line-derived neurotrophic factor (GDNF) instead of nerve growth factor (NGF). 39, 45 This switch subsequently regulates how the sensory neurons relay information from the periphery to the spinal dorsal horn (DH). 27, 50, 53 The appropriate interaction between primary afferents and the spinal cord (SC) during development is necessary for establishing normal responsiveness to external stimuli. Injury during early life, however, has been shown to alter DH neuron development, which can induce altered behavioral responsiveness to thermal and mechanical stimuli in adulthood. 36, 50, 67, 68 It has been hypothesized that this phenomenon is due to altered peripheral A-fiber sensitization along with improper development of glycinergic inhibition 25, 27 ; a notion that was recently supported by our laboratory. 24 In our previous report, we also found that developing cutaneous nociceptors were sensitized to heat and mechanical stimuli in a pattern that differed from adults. 23, 24 As distinct mechanisms may govern injury-induced hypersensitivity in neonates, it would be important to determine whether there was a unique regulator of peripheral sensitization in developing animals. It has been shown that patients with growth hormone deficiency (GHD), along with showing deficits in growth, can also display resting pain. 2, 7 Growth hormone (GH) plays important roles in homeostasis and tissue repair after injury in addition to its growth-promoting effects in children. 18, 69 However, GH-related signaling molecules such as GH release hormone (GHRH) and ghrelin have been found to decrease mechanical and thermal hypersensitivity after inflammation 15, 63 in adult rodents. In addition, recent human studies have shown that GH treatment provides analgesia in a subpopulation of adult patients with fibromyalgia. 3, 4, 9, 10, 31, 34, 40 Growth hormone exerts much of its effects through insulin-like growth factor (IGF)/IGF receptor (IGFr) signaling, but does not Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
bind IGFr directly. 2 IGF-1 synthesis has been shown to increase after tissue injuries 16 and locally produced IGF-1 has been linked to the development of injury-induced hypersensitivity. 44, 72 Moreover, insulin-like growth factor 1 receptor (IGFr1) antagonists block mechanical and thermal hyperresponsiveness during inflammation in adults. 44 Together, these data suggest that GH signaling may also play an important role in pain modulation during postnatal development. Nevertheless, the role of GH in the development of neonatal pain remains unclear. In this study, we tested the hypothesis that a reduction in GH levels during neonatal cutaneous inflammation drives the sensitization of primary afferents and pain-related hypersensitivity, possibly by suppressing afferent-specific IGFr1 upregulation within sensory neurons.
Materials and methods

Animals
Male and female Swiss Webster mice (Charles River) from postnatal day 6 through 21 (6 ;0.5 days around the specified age) were used in these studies. All animals were housed with the mother, which was provided food and water ad libitum and maintained on a 12-hour light/dark cycle. All procedures were approved by the Institutional Animal Care and Use Committee at Cincinnati Children's Hospital Medical Center, under AAA LACapproved practices. No differences between male and female mice were detected for any tests described below, and thus data were combined from both sexes throughout the article. As our recent reports have documented age-related effects of injury on the excitability of primary afferent neurons, we assessed the effects of cutaneous inflammation beginning at 2 different postnatal ages (P7 or P14) to account for any potential developmental effects. 24 
Carrageenan-induced inflammation
Mice were anesthetized under 3% isoflurane, and 3 to 10 mL of 3% carrageenan (in 0.9% NaCl) was injected into the right hairy hind paw skin using a 30-gauge needle with syringe according to our previous procedures. 24 The carrageenan was expelled beginning at the ankle and allowed to fill under the hairy hind paw skin towards the digits. Injections were directed towards the medial side of the hind paw to target the saphenous nerve field as accurately as possible. One microliter per gram body weight was used as a guide for these injections according to previous studies 64 to account for subtle variations in paw size that occurs as a mouse develops during this period of life. At P7, mice were approximately 3 to 4 g in total body weight, whereas mice at P14 were around 7 to 8 g. Using the abovementioned guide, within a given age group, only variations of approximately 1 mL were made. Growth hormone treatments (below) did not alter injection volumes within a given age group. Regardless, ipsilateral and contralateral hind paw edema was measured using calipers to ensure that a similar degree of inflammation was attained at the different ages. All behavioral, electrophysiological, anatomical, or molecular analyses were performed 1, 3, and 7 days after injection of carrageenan and compared with unanesthetized naïve mice at P7 or P14, or with each other.
Growth hormone treatments and side effects analysis
Mouse recombinant growth hormone (GH; GenScript, Piscataway, NJ) was diluted in H 2 O (50 mL) in different concentrations (0.1-0.5 mg/kg) and intraperitoneally injected once per day beginning 3 days before, or once on the day of carrageenan injections at P7 or P14 as indicated. The initial guide that was used for this injection strategy was based on the amount of GH that would be needed to begin modulating systemic GH-mediated signaling without concurrently stimulating growth. 13 The maximum serum concentration of GH detected from this injection regimen in rodents would only reach approximately 100 to 150 ng/ mL, 3 hours after the final injection. By 24 hours after the final dose however, which is when we begin to perform our assessments postinflammation, systemic GH levels should return to normal concentrations (;0-20 ng/mL). 13 Body weight, temperature, and urine ketones were monitored to determine potential side effects of GH administration. Temperature was determined on the thorax using a contact thermocouple connected to a temperature readout device according to previous procedures. 17 Levels of ketones in the urine were determined by applying a small droplet of urine to the testing end of a Ketodiastix (Bayer) and verifying ketone concentration according to the color-coded scale provided by the manufacturer.
siRNA production and in vivo nerve injections
Mice were anesthetized as described above. A small incision was made in the midthigh region exposing the saphenous nerve. The nerve was loosened from the adjacent connective tissue and placed onto a parafilm platform. Then 0.05 to 0.1 mL of 20 mM nontargeting control (siCON) or IGFr1 targeting (siIGFr1) siRNAs (Thermo Scientific, Waltham, MA) was pressure injected into the saphenous nerve using a quartz microelectrode connected to a picospritzer. The control siRNAs used in this study were a pool of 4 nontargeting duplexes that do not target any gene in the mouse genome (Thermo). The targeting sequences used to design each siCON duplex are as follows: 59-UAA GGC UAU GAA GAG AUA C -39, 59-AUG UAU UGG CCU GUA UUA G -39, 59-AUG AAC GUG AAU UGC UCA A -39, and 59-UGG UUU ACU GUC GAC UAA -39. The specific targeting sequence for IGFr1 used for in vivo studies was determined by selecting 4 different targeting sequences (Cat#D-056843; Thermo Scientific) and transfecting Neuro2A cells in vitro according to our previous reports 19 with the individual IGFr1 targeting siRNAs (1) (2) (3) (4) and comparing them to untreated cells or those transfected with the nontargeting control siRNAs (siCON). RNA was isolated from the different culture conditions, reverse transcribed, and cDNAs were used in SYBR Green real-time PCR reactions as described below. The most efficiently targeting siRNA (sequence #1: 59-CCA UCG AGG UUA CUA AUG A -39) was used thereafter for this report. After injections, the incision was closed with a 7-0 silk suture. For P7 mice, siRNAs were injected one day before inflammation, and for P14 mice, siRNAs were injected 2 days before inflammation. This strategy follows a modified version of our previous reports.
21-23
Behavioral analyses
All behavioral experiments were performed in which the experimenter was blinded to the various conditions. siCONinjected control mice that did not receive carrageenan injections were performed separately by a different experimenter. After a 15 to 20 minute acclimation period in the behavior chamber, the mechanical and thermal thresholds were tested as previously described. 42, 68 Mechanical threshold was determined by application of an increasing series of calibrated von Frey (VF) hairs to the medial side of the dorsal surface of the hind paw, which is innervated by the saphenous nerve. After another 10 to 15 minute rest period, a water bath of varying temperatures was used to measure heat sensitivity. Mice were gently held and both hind paws were submerged into the water. Time until a hind paw flexion withdrawal response was detected was recorded as the latency. Twenty seconds was set as a cut-off time. Forty degrees centigrade and 45˚C were tested for P7 cohorts (1-7 days post carrageenan), whereas 45˚C and 50˚C were tested for mice $P14. This follows a similar strategy to that previously described by Marsh et al. 42 and Walker et al. 68 in which different maximal temperatures are required between these 2 ages. Both mechanical and thermal tests were performed 3 times at 5-minute intervals. The average of the 3 trials was determined per mouse, per time point/condition. The average values are reported as mean 6 SEM after normalization to age-matched naives. For siRNA-injected mice, dorsal root ganglion (DRG) receptor expression (using PCR) was verified in the control or IGFr1 targeting groups to confirm validity of behavioral results obtained from these cohorts. In a few instances, individual mice did not achieve significant knockdown and were not included in the analysis.
Ex vivo preparation and intracellular recording
The ex vivo hairy hind paw skin/saphenous nerve/DRG/SC somatosensory system recording preparation was performed as described previously. 20, 22, 24, 33 Briefly, mice were anesthetized with ketamine and xylazine (90 and 10 mg/kg, respectively) and intracardially perfused with oxygenated (95% O 2 -5% CO 2 ) artificial cerebrospinal fluid (aCSF; in mM: 1.9 KCl, 1.2 KH 2 PO 4 , 1.3 MgSO 4 , 2.4 CaCl 2 , 26.0 NaHCO 3 , and 10.0 D-glucose) containing 253.9 mM sucrose at a temperature of approximately 12˚C. The SC (caudal from ;T10) and the right hindlimb were excised and placed in a bath of this oxygenated aCSF. The hairy skin of the right hind paw, saphenous nerve, L1-L5 DRG, and corresponding SC segments were isolated in continuity and then transferred to a recording chamber containing chilled and oxygenated aCSF in which the sucrose was replaced with 127.0 mM NaCl. The skin was then pinned out on a stainless steel grid located at the bath/air interface to allow the dermal surface to be continuously perfused with the aCSF while the epidermis remained dry. The bath was finally warmed to 32˚C before recording.
Intracellular single unit recording was performed in sensory neuron somata contained within the L2 or L3 DRG using quartz microelectrodes (impedance .150 MV) containing 5% Neurobiotin (Vector Laboratories, Burlingame, CA) in 1 M potassium acetate. Sensory neuron somata in the L2/L3 DRG with axons in the saphenous nerve were identified by electrical simulation to the side of the nerve through a suction electrode during intracellular recording. If a cell was found to be driven by this electrical stimulus, then the cutaneous receptive fields (RFs) were localized with a soft brush and/or von Frey filaments. When cells were driven by the nerve but had no mechanical RF, a thermal search was conducted by applying hot (;53˚C) and/or cold (;1˚C) physiological saline to the skin.
Response characteristics of individual DRG cells were determined by first applying mechanical and then thermal stimuli to the hairy skin. For mechanical stimulation, RFs were probed for 1-2 seconds with an increasing series of calibrated VF filaments ranging from 0.07 to 10 g. When feasible, a mechanical stimulator that delivered a digitally controlled mechanical stimulus was also used, which consisted of a tension/length controller (Aurora Scientific, Aurora, ON, Canada) attached to a probe with a 1-mm diameter aluminum tip. Computer-controlled 5-second square waves of 1, 5, 10, 25, 50 and 100 mN were applied to the cell's RF in these instances. To compare these results to those of the VF stimulation, units in milliNewton were converted to grams based on the 1 mm probe diameter. After mechanical stimulation, a controlled thermal stimulus was applied using a 3 3 5 mm contact area Peltier element (Yale Univ. Machine Shop) or saline stimuli as described. The controlled thermal stimulus consisted of a variable cold ramp that started at 32˚C and dropped to approximately 3 to 4˚C, which was held for 2 to 3 seconds and allowed to return slowly to the bath temperature (32˚C). Bath temperature was held for a few seconds (;2-3 seconds) and then a heat ramp was initiated, which delivered an increasing heat stimulus to the RF up to 52˚C. The ramp increases in temperature from 32 to 52˚C in 12 seconds. The 52˚C stimulus was held for 5 seconds and then the ramp returned the RF to 32˚C in 12 seconds. Adequate recovery times (approximately 20-30 seconds) were used between all stimulations. As discussed previously, 20, 24, 57 the repetitive stimulation of the RFs with hot saline was not found to sensitize nociceptors during the recording experiments. No differences were found in recorded fibers from the beginning of an experiment to those obtained at the end.
When fibers were unable to be fully characterized by controlled mechanical and thermal stimulation but were partially characterized by one of the controlled stimuli and brush or saline stimuli, these cells were also included for determination of afferent subtype prevalence and for the properties in which we obtained controlled data. All responses were recorded for offline analysis (Spike2 software; Cambridge Electronic Design, Cambridge, United Kingdom). Conduction velocities of the recorded afferents were then calculated from spike latency and the distance between stimulating and recording electrodes (measured directly along the nerve). Firing rates (FRs) were determined by calculating the peak firing after binning the responses in 200 milliseconds bins.
A total of 738 cells were intracellularly recorded and physiologically characterized in this study. The average number of cells recorded per condition/time point/age was 53, which were obtained from an average of 4 mice per group. The minimum number of mice per preparation was 3 and a minimum of 44 For primary DRG neuron cultures, we followed our originally described procedures 19, 41 but used DRG from P14 male mice. Animals were first anesthetized and intracardially perfused with Hank's balanced salt solution. Dorsal root ganglia (all spinal levels) were then dissected and collected in Hank's balanced salt solution and dissociated using cysteine/papain (0.03%, Sigma, St. Louis, MO; and 20 U/mL, Worthington, Columbus, OH) followed by collagenase II (0.3%, Worthington), and then triturated with fire-polished glass pipettes in F12 complete media (F12 containing 10% fetal bovine serum and 1% penicillin/ streptomycin) before plating onto poly-d-lysine/laminin (20 mg/ mL each; Sigma)-coated glass coverslips (Menzel, Germany) that were placed in 35 mm petri dishes. Cells were allowed to incubate at 37˚C/5% CO 2 for 1 to 2 hours and then flooded with F12 complete media alone (untreated) or media containing 50 ng/mL GH (Genscript). Cells were then allowed to incubate at 37˚C/5% CO 2 for 24 hours. At this time, media was removed and cells were flooded with single-cell PCR buffer (In millimolar: 140 NaCl, 10 glucose, 5 KCl, 10 HEPES, 1 MgCl 2 , and 2 CaCl 2 ). Then individual neurons (n 5 20) that were qualitatively determined to be in the medium to small diameter range were collected using borosilicate electrodes and Cell Tram Vario system (Eppendorf, Hamburg, Germany) under bright field optics using a Leica inverted microscope. Images of the various cell culture conditions were obtained using modified differential interference contrast on a Leica inverted fluorescence microscope.
All collected single cells were used in real-time PCR reactions based on a modified protocol from Kurimoto et al. 30 and Ross et al. 56 Single cells were first expelled from the borosilicate electrodes into individual tubes containing lysis buffer from the Message Booster cDNA Synthesis Kit (Epicentre/Illumina), and prokaryotic spike RNAs (1000 copies of LYS transcripts) were used for internal and reverse transcription controls because internal controls such as glyceraldehyde 3-phosphate dehydrogenase (GAPDH) will consistently vary from single cell to cell. 56 Single-cell RNAs were reverse transcribed with superscript III (Invitrogen Carlsbad, CA) primed by an Oligo (dT) containing a T7 RNA polymerase promoter. cDNAs then underwent in vitro transcription, RNA was purified, and new cDNAs were produced using superscript III. cDNAs were then diluted and ran in duplicate in standard SYBR Green real-time PCR reactions (20 ng/ reaction) on a StepOne real-time PCR machine (Applied Biosystems, Foster City, CA). The forward and reverse primer sequences for GAPDH and LYS are as follows: GAPDH: forward: 59-ATG TGT CCG TCG TGG ATC TGA -39; reverse: 59-ATG CCT GCT TCA CCA CCT TCT T -39; LYS: forward: 59-GCC ATA TCG GCT CGC AAA TC -39; reverse: 59-AAC GAA TGC CGA AAC CTC CTC -39. Glyceraldehyde 3-phosphate dehydrogenase was first tested in each sample to verify acquisition of single-cell cDNAs. However, cycle time (Ct) values for all targets in single-cell PCR reactions were normalized to the LYS spike RNA controls.
Whole dorsal root ganglion or skin RNA isolation, reverse transcription, and real-time PCR
Animals were first anesthetized as described above. The mice were then intracardially perfused with ice cold 0.9% NaCl before dissection of skin or DRG. RNA isolation from the hairy skin was performed using Trizol (Thermo) followed by RNA cleanup with the Qiagen RNeasy Mini Kits, whereas L2 and L3 DRG RNA was isolated using Qiagen RNeasy mini kits for animal tissues using the supplied protocol (n 5 3-5 per condition and time point). RNA concentrations were then determined by obtaining A260 readings on a Nanodrop spectrometer (Thermo). Purified RNA was treated with DNase I (Invitrogen) and then DNased RNA was reverse transcribed using superscript II Reverse Transcriptase (Invitrogen). For real-time PCR, 25 ng samples of cDNA were added to a SYBR Green Master Mix (Applied Biosystems) containing the appropriate primer combinations and run in duplicate on an Applied Biosystems StepOne real-time PCR machine. Forward and reverse primer sequences used in real-time PCR reactions for IL1b, GDNF, NGF, IGFr1, and GAPDH were obtained from Ross et al., 57 Jankowski et al., 20 or Elitt et al. 12 Primer sequences for the GH receptor are as follows: forward: 59-GCC TCT ACA CCG ATG AGT AA -39; reverse: 59-GGA AAG GAC TAC ACC ACC T -39. Primer sequences for tumor necrosis factor-a (TNF-a) are as follows: forward: 59-TCG GAA AGA AAT GTC CCA GGT GGA -39; reverse: 59-TGG AAC TGG TTC TCC TTA CAG CCA -39 and sequences for IL6 are as follows: forward: 59-ACT GAT GCT GGT GAC AAC -39; reverse: 59-CCG ACT TGT GAA GTG GTA TAG -39. Cycle time (Ct) values were normalized to GAPDH, and changes in expression are calculated as a DDCt value that is determined by subtracting the Ct values of the gene of interest from the GAPDH (or LYS) internal control for each sample and compared among samples. Fold change is described as 2 DDCt (Applied Biosystems) and 2-fold change equals 100% change (mean 6 SEM).
Protein isolation and Western blotting
Similar to RNA isolation, animals were first anesthetized as described above and intracardially perfused with ice cold 0.9% NaCl. Skin samples or L2/L3 DRG pooled from 2 mice as indicated were then collected and homogenized in lysis buffer containing 1% sodium dodecyl sulfate (SDS), 10 mM Tris-HCl (pH 7.4), and protease inhibitors (1 mg/mL pepstatin, 1 mg/mL leupeptin, 1 mg/ mL aprotinin, 1 mM sodium orthovanadate and 100 mg/mL phenylmethylsulfonyl fluoride; Sigma Biochemicals). Then 20 mg samples from each condition were centrifuged and boiled 10 minutes in a denaturing buffer containing b-mercaptoethanol and SDS before gel electrophoresis. Samples were then separated on a 7.5% to 16% polyacrylamide SDS-PAGE gel and transferred to a PVDF (Millipore Billerica, MA) membrane that was blocked in specialized LiCor blocking buffer. Membranes were then incubated in primary antibodies overnight at 4˚C (GAPDH: 1:2000, ProSci Inc, Poway, CA; GH: 1:2000, GenScript; IGF-1: 1:1000, Abcam, Cambridge, MA; IGFr1: 1:750, Acris, Rockville, MD). Antibody binding was visualized using 800 or 680 nm infrared dyeconjugated donkey anti-rabbit or donkey anti-chicken secondary antibodies (1:20,000; LiCor, Lincoln, NE) with detection using the LiCor Odyssey Imaging System (LiCor). Settings for detection were consistent between runs. Immunoreactive bands were analyzed by densitometry and quantified using NIH image J (RRID: nif-0000-30467) software. Band intensity was normalized to GAPDH and reported as a percent change (mean 6 SEM). A negative control and a peptide block control were also performed for the GH antibody. In this latter case, an equal dilution of the manufacturer's supplied peptide was incubated with the GH antibody (above) during blot processing. For the negative control, no primary antibody was used. Both controls followed the above procedures.
Data analysis
All data are presented as mean 6 SEM. Behavioral assays were compared using 1-or 2-way repeated measures or standard analysis of variance (ANOVAs) with Holm Sidak or Tukey post hoc tests. Peak FRs, mean peak instantaneous frequencies (IFs) and thresholds to mechanical or heat stimuli were compared through 1-way ANOVA with Holm-Sidak post hoc as appropriate or Kruskal-Wallis 1-way ANOVA on ranks with Dunn post hoc tests. Percent change in protein expression detected from Western blotting and gene expression changes in single cells or whole tissues were analyzed through 1-way ANOVA with Tukey post hoc. Critical significance level was defined at P , 0.05. Rare instances of statistical outliers defined as values greater than 2 SDs away from the mean were not included in the analysis.
Results
Cutaneous inflammation produces a localized reduction in growth hormone levels
To first determine whether cutaneous inflammation altered the levels of GH in the injured skin of neonates, we quantified GH protein in the hairy hind paw skin using Western blot analysis on mice with inflammation induced at P14. We found that neonatal cutaneous inflammation (n 5 3-4 each) significantly decreased the levels of GH protein present in this target tissue one day after carrageenan injection initiated at P14. Hairy skin GH levels returned to that of naive mice 3 days after cutaneous inflammation (Fig. 1A) .
We then delivered a 3-day pretreatment of GH (0.5 mg/kg; 13/d for 3 days) and found that this was sufficient to prevent the reduction in hairy skin GH levels following carrageenan injection at P14 ( Fig. 1A; P . 0.05). Next, we wanted to determine whether the observed GH reduction in hairy skin was specific to the inflamed target tissue or was a broad effect of peripheral inflammation. We thus performed similar Western blot analyses on forepaw and back skin from mice that received carrageenan injection into the hairy hind paw skin and found that no statistically significant differences in GH levels were detected ( Fig. 1B; P . 0.05). Both negative and peptide block controls verified GH antibody specificity for Western blotting. GH injections into naive neonates using this regimen were not found to increase cutaneous levels of GH ( Supplementary Fig. 1 , available online at http://links.lww.com/PAIN/A360). These data suggest that cutaneous inflammation produces a transient GH reduction in the affected skin and a short, low dose GH pretreatment reverses the inflammation-induced GH decrease in the skin.
Exogenous growth hormone treatment blocks injuryinduced mechanical and thermal hypersensitivity
As our above results suggested that we are able to manipulate and restore the levels of GH in the inflamed hairy skin of neonatal mice, we tested the effectiveness of an exogenous GH treatment on the reported 42, 52, 68 mechanical and thermal hypersensitivity during cutaneous inflammation at P7 or P14. We first performed a dose-response analysis based on the above information and previously reported data. 13 Mice were thus treated with one of 3 different doses of GH (0.1-0.5 mg/kg, ip.) once a day beginning 3 days before injury up through the day of inflammation, or another cohort of mice was given a single injection of GH (at 0.5 mg/kg, ip.) at the same time as cutaneous inflammation. We found that inflammation-induced mechanical and heat hypersensitivity one day after injury was blocked by varying doses of the 3-day pretreatment strategy regardless of the age of initial insult. A single injection of GH at the highest dose used, however, was insufficient to block carrageenan-induced hyperresponsiveness to mechanical and thermal stimuli at P14, whereas a single dose of GH partially blunted heat but not mechanical hypersensitivity at P7 (Supplementary Fig. 2 , available online at http://links.lww.com/PAIN/A360).
We therefore assessed the time course of GH effects on neonatal inflammatory hypersensitivity using the dosing regimen that was effective in all behavioral tests (0.5 mg/kg, ip.; 13/d for 3 days before inflammation; see Supplementary Fig. 2 , available online at http://links.lww.com/PAIN/A360). Specifically, mechanical thresholds in the ipsilateral hind paw one day after carrageenan injection (at P14) were significantly decreased compared with baseline, but this returned to normal levels by 3 days ( Fig. 2A ; n 5 12, P , 0.05). However, GH pretreatment completely blocked this decrease at 1 day and showed no differences vs baseline at 3 days ( Fig. 2A ; n 5 9, P , 0.05). A seven-day time point was not analyzed because of the difficulty of mechanical testing on the hairy skin in older mice ($P21). No changes were found in the contralateral limbs in any group at 1 day (not shown).
Heat withdrawal latencies to 50˚C water were significantly decreased 1 day and 3 days (P , 0.05) after P14 carrageenan injection compared with baseline. Heat hypersensitivity returned towards uninjured levels by 7 days postinflammation, but did not fully recover to naive levels. Growth hormone pretreatment, however, completely inhibited the carrageenan-induced reduction in heat withdrawal latency at all time points (Fig. 2B) . No Figure 1 . Cutaneous growth hormone (GH) protein expression with or without exogenous GH delivery after hairy skin inflammation at P14. (A) At P14, GH was found to be significantly reduced in the inflamed hairy hind paw skin 1 day after peripheral injury. Levels in the inflamed area were reduced 35% (69%) relative to those observed in naive hairy skin, but returned to naive levels by day 3 (D3). Treatment of mice with exogenous GH for 3 days before injury was able to block the reduction in GH levels found after cutaneous inflammation. (B) Analysis of naïve forepaw (FP) or back skin, or cutaneous tissue from these same regions obtained from mice 1 day post carrageenan injection into the hairy hind paw skin at P14, showed no differences in GH levels. The decrease in GH expression that was found in the FP skin after hind paw skin inflammation was determined to be a 29% (610%) reduction, but this was not found to be statistically significant vs naive FP skin. n 5 3 to 4/group, *P , 0.05 vs naive, #P , 0.07 vs naive; 1-way ANOVA/Tukey post hoc. ANOVA, analysis of variance. www.painjournalonline.com 337 differences were detected between any group during a 45˚C heat stimulus (P . 0.05, not shown). Growth hormone pretreatment at P14 had no effect on baseline mechanical sensitivity (ie, without injury) or heat withdrawal times compared with untreated naives (see Supplementary Fig. 3 , available online at http://links.lww. com/PAIN/A360). These data suggest that an exogenous GH treatment can block mechanical and thermal hypersensitivity if given before neonatal cutaneous inflammation.
Exogenous growth hormone pretreatment blocks cutaneous afferent sensitization during neonatal peripheral inflammation
To then determine the effects of GH pretreatment on the response properties of primary sensory neurons, we performed single unit recordings with our neonatal ex vivo hairy hind paw skin/saphenous nerve/DRG/SC recording preparation, at 1 day and 3 days postinflammation. Two categories of sensory afferents are detected based on conduction velocity (CV) during development due to ongoing myelination. 24, 28, 70 "A"-fibers were defined as those that conduct at least twice as fast as the other sensory neurons ("C"-fibers) in a given experiment. We do acknowledge however, that based on these criteria, some fibers could be classified as "A"-fibers if they conducted at the higher end of the adult C-fiber range for rodents (1.2 m/s). 20, 29 However, it should be noted that only 13 cells of the 738 recorded in our study fell into this category (ie, were classified as "A"-fibers despite conducting slower than 1.2 m/second). Furthermore, this categorization is consistent with previous reports analyzing response properties of neonatal sensory neurons. 24, 54, 70 At P14, the average CVs for A-fibers were 5.14 m/s, and the average CVs for C-fibers were 0.56 m/s. No differences in A-or C-fiber CVs were found between any of our groups.
We detected no differences after carrageenan injection in the rapidly or slowly adapting low threshold mechanoreceptors (faster conducting cells with narrow spikes), nor were there any differences detected in the low threshold mechanically sensitive and cold-sensitive C-fibers (CMC; slower conducting cells with narrow spikes). There were also no differences in the mechanically insensitive but cold (CC) or heat (CH) sensitive C-fiber neurons (slower conducting, broad spiking) among any of our experimental groups (not shown). Therefore, the remainder of the study focused on the myelinated nociceptors (faster conducting, broad spiking afferents) that were mechanically sensitive, and sometimes thermally sensitive ("A"-high threshold mechanoreceptors [A-HTMRs]: AM or A-polymodal [APM]), or the unmyelinated nociceptors (slower conducting, broad spiking fibers) with these types of responses ("C"-HTMR: CM or CPM).
Consistent with our previous report 24 at P14, CPM mechanical FRs, heat FRs and heat peak IFs were all increased (n 5 7
[mechanical] and n 5 5 [heat]) 1 day after carrageenan-induced inflammation (P , 0.05) compared with naives (n 5 10 and n 5 7, respectively; P , 0.05). These alterations in C-fiber response properties were all blocked by GH pretreatment (n 5 4 for both mechanical and heat responsive cells; P . 0.05; Fig. 3A-C) . No differences in mechanical or heat firing in CPMs were found between our groups at 3 days postinflammation ( Fig. 3 ; inflammation only: n 5 17 [mechanical] and n 5 11 [heat]; inflammation 1 GH: n 5 6 [for both mechanical and heat responsive cells]). Meanwhile, the CM mechanical FRs and thresholds had no statistical changes at any time point between any groups (n 5 4-9; not shown). A-fiber HTMR mechanical FRs were not found to be different post carrageenan (n 5 10) compared with naives (n 5 13; P . 0.05; not shown). Heat FRs were also unaffected in the A-HTMR neurons at 1 day (n 5 3-6; not shown). These data suggest that P14 cutaneous inflammation sensitizes CPM nociceptors, but not A-fiber HTMRs; however, this can be blocked by GH pretreatment.
A short course of low dose growth hormone in inflamed mice does not induce classic side effects of extended growth hormone therapy or alter cutaneous inflammatory responses to carrageenan
We next determined whether our transient, low dose GH therapy produced any of the known side effects of prolonged GH therapy in our mouse model of cutaneous inflammation such as altered body weight, temperature or induction of hyperglycemia. 6, 60, 63 We found that the highest dose (0.5 mg/kg ip.; 13/d for 3 days before inflammation) used to effectively block mechanical and thermal responsiveness in our inflamed mice was not sufficient to significantly alter body weight at P14 (Fig. 4A ; n 5 4-14; P . 0.05), nor did it produce detectable ketones in the urine (indirect measure of insulin resistance; not shown). While we did detect Figure 2 . Effects of growth hormone (GH) pretreatment on peripheral hypersensitivity after P14 carrageenan injection. (A) Mechanical hypersensitivity during P14 inflammation (measured as a percent change in thresholds relative to baseline) was blocked by GH pretreatment at 1 day. No differences were found between mice injected with carrageenan alone or those treated with carrageenan plus GH at 3 days; however, both of these groups differed from mice that received carrageenan only at the 1 day time point. (B) Hairy skin inflammation also reduced the heat withdrawal latencies to 50˚C water at 1 day and 3 days post carrageenan, but this was completely blocked by GH pretreatment at all time points tested. By 7 days, a partial restoration of heat hypersensitivity was found in mice with carrageenan injection only; however, these mice were not different than those treated with GH at this 7 days time point. Growth hormone-treated mice with hairy hind paw skin inflammation did not change relative to their baseline levels at any time point postinflammation. *P , 0.05 vs baseline and GH-treated mice; #P , 0.05 vs baseline, but not time-matched GH-treated mice; 2-way RM ANOVA/Holm-Sidak. ANOVA, analysis of variance; RM, repeated measures. a significant increase in body temperature in mice that were injected with carrageenan compared with uninjured naives, this was not further affected by the injection of GH ( Fig. 4B ; P , 0.05).
As our results suggested robust effects of GH pretreatment on neonatal hypersensitivity to cutaneous inflammation, we wanted to determine whether these effects were due to alterations in the peripheral inflammatory response. We thus measured paw edema and also performed real-time PCR on the hairy hind paw skin for various cytokines and growth factors in our cohorts. We found that GH pretreatment did not alter carrageenan-induced paw edema ( Fig. 4C ; P . 0.8), and had no effects on the induction of cutaneous cytokines and growth factors after P14 inflammation (Fig. 4D) . Of the numerous factors that were screened in this study, only the inflammatory cytokine interleukin 1b (IL1b) was found to be significantly upregulated in the skin after carrageenan injection into the hairy hind paw skin at P14, but GH pretreatment did not prevent its upregulation. No increases in NGF or TNF-a mRNA were found in the skin after P14 inflammation (Fig. 4D) . We did not detect significant levels of GDNF or IL6 mRNA in any group using these reaction conditions and primer sets (not shown). Thus, GH does not seem to induce classic side effects of extended GH therapy, and the GH effects on peripheral hypersensitivity during neonatal inflammation are unlikely to reflect a suppression of the inflammatory response within the skin.
Growth hormone pretreatment regulates mechanical and thermal hypersensitivity after cutaneous inflammation at P7
Since our data showed a profound effect of GH on neonatal hypersensitivity to inflammation at P14, we wanted to assess whether similar results could be obtained in younger mice (P7). Overall, we found highly similar effects of GH on carrageenaninduced hypersensitivity when injury was sustained at P7. We found that GH was also reduced specifically in the hairy skin after inflammation at P7 ( Supplementary Fig. 4A , B; n 5 3-4, available online at http://links.lww.com/PAIN/A360), which could be prevented with a GH pretreatment (P . 0.05). In addition, the mechanical and heat hypersensitivity (at 45˚C) that was observed in these younger mice was also blocked with exogenous GH pretreatment. (Supplementary Fig. 4C , D; n 5 11-13, P , 0.05, available online at http://links.lww.com/PAIN/A360). Similar results on heat hypersensitivity were also detected at lower temperatures analyzed. Although carrageenan injection significantly decreased withdrawal latencies in response to a 40˚C heat stimulus at 1 day compared with baseline (221.7% 6 9.9%; P , 0.05), no differences in heat withdrawal latency were detected in the GH-treated group (23.2% 6 10.2%; P . 0.05). No differences were found among any of our groups at the 3 or 7 day time points at this temperature however (not shown). Finally, no changes were found in the contralateral limbs in any group after P7 inflammation (not shown).
Interestingly, when comparing raw baseline values between our groups, the mechanical withdrawal thresholds for both ipsilateral and contralateral hind paws were decreased in the GHtreated group compared with the baseline thresholds in untreated/naive neonates at P7 (see Supplementary Fig. 3 , available online at http://links.lww.com/PAIN/A360); P , 0.05; not shown). In the absence of injury, GH pretreatment also seemed to increase the baseline withdrawal time to 45˚C heat compared with baseline latencies of untreated/naive mice at P7. However, GH did not affect baseline withdrawal latencies to 40˚C (see Supplementary Fig. 3 , available online at http://links.lww. com/PAIN/A360); P , 0.05; not shown). This effect did not however alter the results found at the various time points postinflammation. In other words, these alterations in baseline at the early age cannot account for the apparent beneficial effects of GH after injury as effects on baseline responses were only found at P7 and not P14 (see Supplementary Fig. 3 , available online at http://links.lww.com/PAIN/A360). When assessing the response properties of primary afferents using ex vivo recording in these P7 cohorts, we found that A-HTMR peak mechanical FRs were increased (n 5 10; P , 0.05) at 1 day postinflammation compared with naive cells (n 5 7). However, GH pretreatment in the inflamed mice produced mechanical responsiveness similar to naïve levels at 1 day (n 5 7, P . 0.05). No differences in mechanical firing were found between our groups at 3 days ( Supplementary Fig. 5A , available online at http://links.lww.com/PAIN/A360; inflammation only: n 5 5; inflammation 1 GH: n 5 15). Although peak heat FRs were increased in A-HTMR neurons after carrageenan injection, this did not reach statistical significance (P , 0.1). Peak heat IFs however, were found to be increased in "A"-fiber nociceptors (n 5 3) 1 day after carrageenan injection into the hairy skin ( Supplementary Fig. 5B , available online at http://links.lww.com/ PAIN/A360); P , 0.05). Growth hormone also seemed to restore heat firing; however, we were only able to record from one heat responsive A-fiber at 1 day and one A-fiber at 3 days in these mice. Therefore, we combined data from both time points to try to obtain at least some basic information regarding heat hypersensitivity in A-fiber HTMR neurons from inflamed mice treated with GH. When combining both time points, GH pretreatment was found to prevent inflammation-induced heat hypersensitivity in A-HTMRs during P7 inflammation (n 5 2; Supplementary Fig. 5B , C, available online at http://links.lww.com/PAIN/A360). The mechanical and heat FRs in the CPM and CM neurons displayed no obvious changes postinflammation at P7 and these were also unaffected by GH pretreatment (CPM: n 5 4-17 [mechanical], n 5 4-11 [heat]; CM: n 5 5-9; P . 0.05, not shown). Similar results were also found even if we combined all C-HTMRs (CM and CPM; n 5 11-23; P . 0.05), thus supporting the notion that alterations in primary afferents during P7 cutaneous inflammation are restricted to sensitization in the faster conducting, broad spiking sensory neurons (A-fiber nociceptors), but a GH pretreatment can potentially block these effects. The average CV for A-fibers was 4.04 m/s and average CV for C-fibers was 0.52 m/s at P7.
When assessing other potential effects of GH on the P7 groups, we detected a small increase in body weight in P7 mice injected with carrageenan only, but GH had no effects on body weight in inflamed mice. We did find a small increase in body temperature at P7 in inflamed mice treated with GH relative to naive (P , 0.05); however, the temperatures in these mice were not different than mice that received carrageenan alone ( Supplementary Fig. 6A, B ; n 5 4-12; P . 0.05, available online at http://links.lww.com/PAIN/ A360). At P7, carrageenan induced a similar level of paw edema in mice with GH pretreatment to that observed in mice with carrageenan injection alone ( Supplementary Fig. 6C , available online at http://links.lww.com/PAIN/A360). Finally, significant increases in cutaneous IL1b and GDNF were found in inflamed mice vs naives at P7, but GH had no effects on the inflammationinduced upregulation of these factors in the skin. No changes in NGF or TNF-a were found in the skin after P7 cutaneous inflammation and GH did not alter this result ( Supplementary Fig.  6D , available online at http://links.lww.com/PAIN/A360).
Growth hormone regulates the expression of insulin-like growth factor 1 receptor in sensory neurons
We next investigated potential downstream receptor mechanisms within sensory neurons underlying GH effects. We therefore first performed real-time PCR on the L2/L3 DRG from mice with cutaneous inflammation. We surprisingly did not detect any differences in the expression of the GH receptor (GHr) in the DRG of mice inflamed at P7 (230.6 6 13%) or P14 Figure 4 . Analysis of body weight, temperature, paw edema, and mRNA expression of selected cytokines and growth factors in skin after GH pretreatment in mice after P14 inflammation. At P14, no differences in body weight were observed in any of the 3 groups (A); however, carrageenan injection induced an increase in body temperature that was similarly observed in the GH treatment group (B). *P , 0.05 vs naive; n 5 4 to 11/group; 1-way ANOVA/Holm-Sidak post hoc. Carrageenaninduced paw edema was not affected by a GH pretreatment regimen (C). Only IL1b was upregulated in the hairy hind paw skin of P14-inflamed neonates (D). Growth hormone-treated neonates with cutaneous inflammation also showed upregulation of this cytokine in the skin. Although both groups showed significant upregulation of IL1b in the skin after inflammation, there were no statistically significant differences between these groups in regards to relative gene expression. (240.7 6 23.3%) compared with age-matched naïve DRG (P . 0.05). Our previous data however 24 showed a significant increase in IGFr1 at both ages, which is a known downstream mediator of GH function in other systems 55 and has also been linked to mechanical and thermal hypersensitivity after inflammation. 44, 72 Therefore, to test if GH regulated the expression of IGFr1 specifically in sensory neurons, we dissociated P14 DRG and treated individual cultures with growth hormone. PCR analysis of single DRG neurons (n 5 20) showed that treatment of primary cultures with GH not only reduced the numbers of individual cells that expressed IGFr1, but the cells that contained IGFr1 in the GH-treated cultures showed significantly reduced expression of this receptor (P , 0.05) compared with untreated neurons (Fig. 5A-C) . Using Western blot, we found that carrageenan induced an increase in IGFr1 protein in the DRG of mice at P14. This increase however, was blocked by pretreatment with GH (Fig. 5D) . Interestingly, we found no changes in IGF-1 in the skin from any group (Fig. 5E) . These data suggest that IGFr1 may be one target by which GH could regulate peripheral hypersensitivity within sensory neurons during neonatal cutaneous inflammation.
3.7. Primary afferent knockdown of insulin-like growth factor 1 receptor blocks peripheral hypersensitivity and alterations in sensory neuron response properties during neonatal cutaneous inflammation Based on the above information, we then used a nerve-specific siRNA-mediated knockdown strategy to specifically inhibit the inflammation-induced upregulation of IGFr1 in injured saphenous afferents. Insulin-like growth factor 1 receptor expression in the DRG (n 5 6-14) of mice injected with nontargeting siRNAs (siCON) plus inflammation confirms our previous report of a significant increase in IGFr1 mRNA, 1 day after inflammation at P14 (95.3 6 14.8%; P , 0.05 vs naive). Injection of IGFr1 targeting siRNAs (siIGFr1) in inflamed mice prevented this increase (49.7 6 14.9%; P . 0.05). Western blot results (n 5 3-4) also shows that siIGFr1 injection successfully blocked the inflammation-induced increase in IGFr1 protein in the DRG (P , 0.05, Fig. 6A ).
We then assessed behavioral hypersensitivity during cutaneous inflammation, in addition to afferent sensitization at P14. Ipsilateral hind paw mechanical thresholds at 1 day postinflammation were again decreased from baseline in the siCON 1 carrageenan group (n 5 11; P , 0.05), whereas in the siIGFr1 1 carrageenan group (n 5 10), the thresholds only partially decreased from their baseline (P , 0.05, Fig. 6B ). Again no changes were found in the contralateral limbs in any group at 1 day (not shown). At 50˚C, the heat withdrawal latencies were significantly decreased from baseline in the siCON group (P , 0.05), but no significant changes were found in the siIGFr1-injected mice with inflammation (P . 0.05, Fig. 6C, D) . The heat withdrawal latencies at 45˚C were not different between baseline and 1 day inflammation for either siRNA-injected group at P14 (not shown). No effects of siCON injection were detected for mechanical sensitivity in mice at P14. The siRNA injection strategy also did not alter behavioral responses to heat stimulation ( Supplementary Fig. 7 , available online at http:// links.lww.com/PAIN/A360).
Single unit recording using our ex vivo preparation showed no differences in mice with siCON injection plus carrageenan compared with mice that only received carrageenan injection ( Table 1) , therefore data from these 2 groups were combined to enhance statistical power. At P14, CPM mechanical FRs (n 5 14), heat FRs and heat IFs (n 5 12) all increased in the siCON group (P , 0.05) after carrageenan compared with naïves (n 5 10 [mechanical] and n 5 7 [heat]). siIGFr1 injection prevented the inflammation-induced alterations in CPM neurons at this age (n 5 15 [mechanical] and n 5 11 [heat]; P . 0.05, Fig. 6D-F) . Similar effects of IGFr1 knockdown were found on the CM neurons at this age for the mechanical FRs (naive: 1.8 6 0.3 Hz, n 5 8; siCON 1 carrageenan: 4.9 6 0.7 Hz, www.painjournalonline.com 341 n 5 12, P , 0.05 vs naive; siIGFr1 1 carrageenan: 3.5 6 0.6 Hz, n 5 6, P . 0.05 vs naive). A-HTMR mechanical FRs, however, were not different between any group (n 5 6-15; not shown); Finally, we were only able to record from one A-fiber that responded to heat at P14 from each of the siCON and siIGFr1 groups, thus we were unable to assess the effects of IGFr1 knockdown on A-fiber heat responses at this age. To again assess whether similar effects of GH could be found on IGFr1 expression or whether nerve specific IGFr1 inhibition could also blunt peripheral hypersensitivity found in younger neonates with inflammation, we performed similar experiments described above in these younger cohorts. As was found with P14 inflammation, P7 carrageenan injection upregulated IGFr1 in the DRG, which was prevented by GH pretreatment, but inflammation did not alter cutaneous IGF-1 levels (Supplementary Fig. 8 ; n 5 3-4, available online at http://links.lww.com/PAIN/ A360). In addition, siRNA mediated knockdown of IGFr1 in sensory neurons prevented the development of pain-related hypersensitivity (n 5 9-10), and the sensitization of A-HTMRs normally seen after P7 inflammation ( Supplementary Fig. 8 , available online at http://links.lww.com/PAIN/A360). siCON injection alone slightly increased mechanical thresholds at P7, but did not alter heat (45˚C) withdrawal latencies (see Supplementary  Fig. 7 , available online at http://links.lww.com/PAIN/A360). These data suggest that afferent-selective knockdown of IGFr1 blocks peripheral hypersensitivity and alterations in sensory neuron response properties during neonatal cutaneous inflammation similar to GH pretreatment. Comparison of the response properties of A-HTMRs, CPM, or CM fibers in mice at P7 or P14 with hairy skin inflammation alone or those with siCON injection plus inflammation as assessed with ex vivo recording. 
Discussion
Growth hormone and nociceptor sensitization
The initial postnatal period of life is a critical stage for the development of the peripheral nervous system, 1, 8, 31, 32, 62 and early life injury produces long-term alterations in nociceptive processing. 14, 67 Pain also occurs after injury in pediatric patients at all ages and we observe similar effects in developing mice after injury 24 ( Fig. 2, Supplementary Fig. 4 , available online at http:// links.lww.com/PAIN/A360). Furthermore, insults sustained during development induce patterns of sensory neuron sensitization 20, 23, 24 that differ from those seen in adults. 46 Thus the specific mechanisms by which pain may develop in neonates could be unique. Here we found that cutaneous inflammation in neonatal mice produced a transient reduction in GH levels selectively in the affected skin, which corresponded with the development and resolution of mechanical and thermal hypersensitivity during inflammation. Pretreatment of inflamed neonatal mice with exogenous GH prevented this hypersensitivity and blocked all of the injury-induced alterations in cutaneous afferents (Figs. 1-3 , Supplementary Figs. 4 , 5, available online at http:// links.lww.com/PAIN/A360), possibly by preventing the upregulation of IGFr1 within sensory neurons (Figs. 5, 6 , Supplementary  Fig. 8 , available online at http://links.lww.com/PAIN/A360).
Children with GHD 2,7,18 display a resting pain, 2 which suggests that GH levels may have robust effects on sensory function during early life when the peripheral nervous system is undergoing normal functional and neurochemical changes. 24, 27, 39, 45 During development, sensory neurons change their phenotype 45, 70 as myelinated afferents lose heat sensitivity during the first week of life 70 while "C"-fibers gain heat sensitivity during the second week. 24 Nerve growth factor and GDNF likely play a role in this normal phenotypic switch 24, 39, 45, 53 in addition to afferent sensitization after injury. 20, 22, 24, 54 However, our data also suggest that GH may be one additional factor involved in shaping sensory responsiveness specifically for how the afferents respond to neonatal injuries and generate a pain state ( Figs. 1-3 ; Supplementary Figs. 3, 5 , available online at http://links.lww. com/PAIN/A360). Because GH can influence the functional responsiveness of primary afferents during developmental inflammation, it will be important in the future to determine whether GH also has the ability to affect normal development of the peripheral sensory system and whether GH has similar effects after injury at other ages (ie, adults).
Interestingly, we observed an effect of GH on normal behavioral responses at P7 specifically. Growth hormone pretreatment reduced mechanical thresholds and increased heat withdrawal latencies in uninjured mice only at P7 (Suppl. Fig. 4 , available online at http://links.lww.com/PAIN/A360). This change in mechanical and thermal sensitivity in the P7 mice essentially produced thresholds/latencies that were similar to naive P14 mice. As GH levels are known to increase over time during early life to enhance normal growth and development, artificial delivery of GH to a very young mouse may hasten the development of the peripheral sensory system even under our conditions in which we are using very low doses. 55, 61 However, the fact that we are performing these tests on the hairy skin and not the glabrous skin may be another factor, as this technique becomes increasingly more difficult to perform as the animals get older. This is also the reason we did not perform these mechanical tests at 7 days post-P14 inflammation. Regardless, mice treated with GH still displayed a complete block of mechanical and heat hypersensitivity provoked by cutaneous inflammation (Fig. 2, Supplementary. Fig. 4 , available online at http://links.lww.com/PAIN/A360).
Growth hormone has well-documented effects on growth and metabolism, 18, 69 and extended GH treatment in patients is known to produce side effects such as increased weight gain, transient fever or hyperglycemia. We found that a short course of low dose (0.5 mg/kg, ip.; 13/d for 3 days before inflammation) GH was able to reverse pain-like behaviors (Fig. 2 , Supplementary. Fig. 4 , available online at http://links.lww.com/PAIN/A360) induced by cutaneous inflammation without inducing these classic side effects or growth-promoting effects 13 of extended GH delivery in mice. Furthermore, the GH pretreatment regimen did not alter paw edema during inflammation, nor was it able to block select cytokine/growth factor production (IL1b, GDNF) in the skin (Figs. 4, Supplementary Fig. 6 , available online at http:// links.lww.com/PAIN/A360; not shown). Although it unclear how GH is reduced in the periphery during inflammation, our data suggest that subtle changes in peripheral GH levels may have profound effects on sensory function after injury possibly through direct effects on the afferents (Figs. 5, 6, Supplementary Fig. 8 , available online at http://links.lww.com/PAIN/A360). Future studies will be needed however to fully confirm this notion.
Growth hormone regulates afferent sensitization possibly by suppressing insulin-like growth factor 1 receptor upregulation
The GHRH-GH-IGF-IGFr system is important for the development of body growth and repair after tissue injury. 32, 55 Similar to GH releasing molecules such as ghrelin or GHRH, 15, 63 IGF-1 and its receptor IGFr1 have also been demonstrated to be involved in nociceptive processing 16, 44 in adult rodents possibly by modulating neuronal excitability. 72 Interestingly, in mice overexpressing IGF-2, studies have found reduced sensory innervation of the skin, which may play a role in peripheral responsiveness. 50 Although we did not assess IGF-2, we did not detect any significant alterations in IGF-1 in the skin during neonatal cutaneous inflammation, nor was our transient, low dose GH therapy able to alter IGF-1 in the skin (Fig. 5,  Supplementary Fig. 8 , available online at http://links.lww.com/ PAIN/A360). However, we did observe an upregulation of IGFr1 in the DRG 24 ( Fig. 5, Supplementary Fig. 8 , available online at http:// links.lww.com/PAIN/A360). Insulin-like growth factor 1 receptor is expressed in medium-and small-diameter DRG neurons, 8 which are likely the cells that are experiencing sensitization during inflammation. Because GH can directly modulate the expression of IGFr1 in single primary afferent neurons (Fig. 5) , we sought to determine whether IGFr1 upregulation was one possible mediator of the observed hyperresponsiveness within sensory neurons that was downstream of reduced GH levels in the skin. Similar to GH pretreatment, we found that afferent-selective knockdown of IGFr1 during neonatal inflammation also prevented the injury-induced alterations in cutaneous afferents in addition to mechanical and thermal hypersensitivity (Fig. 6, Supplementary Fig. 8 , available online at http://links.lww.com/PAIN/A360).
Mechanistically, this may due to the fact that GH can modulate IGFr1 transcription through one of the many transcription factors that are known to be activated by GH signaling such as serum response factor or ELK1. 66 Each of these factors has binding sites in the upstream promotor region of IGFr1 (MatInspector software) and has been shown to act as transcriptional repressors under certain contexts, 35 which could be at play in our sensory neurons. Thus, loss of GH could reduce the activation of the transcriptional repressors, subsequently permitting IGFr1 upregulation in the DRG. Insulin-like growth factor 1 receptor would then have the ability to increase the responsiveness of DRG neurons to mechanical and thermal stimuli 44, 72 by modulating excitability 72 or by regulating 24 However, this will need to be confirmed in future experimentation. Although a loss of cutaneous GH may seem counterintuitive during injury because it is a known tissue repair molecule, 35 the transient nature of this loss may serve a role in dynamic IGFr1 upregulation in the DRG to subsequently modulate mechanical and thermal responsiveness (ie, pain), which is itself a protective measure for tissue repair. Although our results do not completely confirm whether GH is acting directly or indirectly on the sensory neurons, one plausible mechanism by which GH acts within sensory neurons to mediate hypersensitivity to peripheral inflammation in neonates is through its effects on IGFr1 upregulation.
Clinical significance
Growth hormone has been reported to be an effective pain therapy for GHD children and patients with erythromelalgia. 7, 47 Other reports have also shown that GH treatment is an effective pain therapy for patients with fibromyalgia. 3, 4, 9, 10, 31, 34, 40 However, the effect in fibromyalgia patients was mainly found in those with corresponding low IGF-1 levels. Our data show no effects of neonatal inflammation or GH pretreatment on IGF-1 in the skin (Fig.  5, Supplementary Fig. 8 , available online at http://links.lww.com/ PAIN/A360). Although future studies would be needed to confirm, this may suggest that the link to IGF-1 levels and the effectiveness of a GH therapy may be specific to widespread muscle pain disorders in adults and not neonatal inflammatory pain states. Nevertheless, our results show that GH has profound effects on injury responses during postnatal development, suggesting that a short course of low dose GH replacement therapy may eventually be used as an effective pharmacological treatment strategy for neonatal pain that does not cause unwanted side effects typically seen with extended GH delivery in humans. 2, 51 As neonatal injury is known to alter primary afferent function 24 which can reorganize the developing DH if initiated at early ages, 67 this strategy may also mitigate the longterm consequences of early life insult on adult nociceptive processing. 14, 67 Studies on the effects of localized GH delivery in acute pediatric pain or the effects of early life GH therapies on longterm hyperalgesic priming will be important in the future.
